Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Quarterly results
AFFYMAX INC (AFFY) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/24/2014 8-K Quarterly results
07/17/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "EX - 99.1",
"EX - 99.2"
06/24/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Limited Continuation of Company"
06/13/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Affymax and Takeda Announce Termination of OMONTYS® (peginesatide) Product Collaboration and License Agreement"
05/14/2014 8-K Other Events
08/20/2013 8-K Form 8-K - Current report
06/07/2013 8-K Entered into consulting agreement
04/23/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/01/2013 8-K Other Events
02/25/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS ® (peginesatide) Injection"
11/08/2012 8-K Quarterly results
Docs: "AFFYMAX REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS"
08/08/2012 8-K Quarterly results
Docs: "AFFYMAX REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS"
07/12/2012 8-K Form 8-K - Current report
05/07/2012 8-K Quarterly results
Docs: "AFFYMAX REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS — $58 million in milestones earned"
04/27/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "OMONTYS® INJECTION NOW AVAILABLE FOR ADULT CHRONIC KIDNEY DISEASE PATIENTS ON DIALYSIS IN THE UNITED STATES — Only Once-Monthly Erythropoiesis-Stimulating Agent Launched In The United States"
03/28/2012 8-K Form 8-K - Current report
03/14/2012 8-K Quarterly results
Docs: "AFFYMAX® REPORTS YEAR END 2011 FINANCIAL RESULTS - Provides Financial Guidance for 2012 -"
02/27/2012 8-K Form 8-K - Current report
12/15/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "TAKEDA AND AFFYMAX PROVIDE UPDATE ON PEGINESATIDE COMMERCIALIZATION RIGHTS IN JAPAN"
12/08/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA ADVISORY COMMITTEE VOTED IN FAVOR OF BENEFIT/RISK PROFILE FOR PEGINESATIDE FOR TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS ON DIALYSIS"
11/09/2011 8-K Form 8-K - Current report
11/09/2011 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "AFFYMAX AND JANSSEN BIOTECH SETTLE PATENT DISPUTE"
09/30/2011 8-K/A Form 8-K - Current report [amend]
08/11/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "AFFYMAX® RECEIVES $10 MILLION MILESTONE PAYMENT FOR FDA FILING OF NEW DRUG APPLICATION FOR HEMATIDE™/PEGINESATIDE",
"AFFYMAX ANNOUNCES ASSIGNMENT OF MARCH 27, 2012 PDUFA DATE FOR PEGINESATIDE NEW DRUG APPLICATION"
08/08/2011 8-K Quarterly results
Docs: "AFFYMAX® REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS - Reaffirms Guidance for 2011 -"
07/27/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "AFFYMAX AND TAKEDA ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR PEGINESATIDE"
05/31/2011 8-K Form 8-K - Current report
05/26/2011 8-K Submission of Matters to a Vote of Security Holders
05/09/2011 8-K Quarterly results
Docs: "AFFYMAX® REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS"
03/30/2011 8-K Form 8-K - Current report
03/22/2011 8-K Form 8-K - Current report
03/10/2011 8-K Quarterly results
Docs: "AFFYMAX® REPORTS YEAR END 2010 FINANCIAL RESULTS"
03/07/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/04/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy